NuCana PLC (NCNA)

News: https://ir.nucana.com/news-releases/news-release-details/nucana-announces-encouraging-data-nuc-3373-combination-anti-pd-1

4.80 pre mkt (up 7%) big news is what ppl saying,cash runway 2029,most interesting is “all outstanding series A warrants cancelled (59.5m warrants cancelled)”

Closed in after mkt nhod,last 15 trades were above the ask and ask is now $4.66
Looking good for pre mkt as ZERO BORROW continues.

Nhod,up 18% ,gotta love zero borrow plays that move freely with no shorts destroying it

NCNA,bio pharma,zero borrow,post r s play,2m float,moving freely,10Xs relative volume is key here,institutional buying up 80%,excellent chart,bottom reversal,went up in death hr,watch for volume surges any minute ,had pops to $5 pre-mkt
I am in 4.05
Good skill everyone!!

https://ca.finance.yahoo.com/news/nucana-reports-second-quarter-2025-200500809.html

NCNA top in

NCNA beasting to new highs

NCNA monster post RS

NCNA POST RS POP

NCNA: effective August 8,2025 a one for 200 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

Got just enough

To hang in there like a Johnny on the Spot

Stocktwits CCTVon
8:11 AM
$NCNA 4 hour chart looks like further movement towards .07, holding VWAP well too. Running out of fuel on the daily and may have a pullback shortly after. Still love their cancer research and think longer term this could see a buyout but their cancellation of this warrants should be a bullish indicator something is brewing

Wow gonna be nice bounce $1.3 than offer hit drop .07 than bounce .31 than down .05 ...now .06 curl up chart......I think. 0.10+ next week

NCNA..............................https://stockcharts.com/h-sc/ui?s=NCNA&p=W&b=5&g=0&id=p86431144783

NCNA announces encouraging initial data from phase 1b/2 study of NUC-3373 in combination with pembrolizumab or docetaxel.
Learn more: bit.ly/3UKQDX3
#oncology #tumor #Cancer

Pps holding .06 extremely strong......bold well .07 Monday here

Very strong buying for a reason ...we shall see Monday

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update
Initiation of Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma

Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data in 2026

Additional Data from the Ongoing Phase 1b/2 Study of NUC-3373 in Combination with Pembrolizumab Remain on track for 2025

Anticipated Cash Runway Extended into Q4 2026 to Support Key Value-Driving Milestones and Complete the Expansion Study of NUC-7738

EDINBURGH, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines.

“We have entered 2025 with a clear focus on the advancement of our pipeline through key milestones, into late-stage development, and towards commercialization,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. “Our lead program, NUC-7738, continues to show significant promise. NUC-7738 is a novel agent that profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. In our ongoing Phase 1/2 NuTide:701 study, we have observed a favorable safety profile, meaningful tumor volume reduction and prolonged progression free-survival in patients with PD-1 inhibitor refractory and resistant metastatic melanoma. Based on these compelling results, we have recently initiated an expansion trial of NUC-7738 in an additional 28 patients with PD-1 inhibitor-resistant melanoma, that supports our registrational path. Based on this, we plan to meet with the U.S. Food and Drug Administration to determine the optimal regulatory strategy forward towards commercialization.”

Mr. Griffith continued, “Turning to our second program, NUC-3373 is a targeted thymidylate synthase inhibitor with immune modulating properties. We are encouraged by the data from the ongoing Phase 1b/2 NuTide:303 study. This study is evaluating NUC-3373 in combination with pembrolizumab in patients with advanced solid tumors, and NUC-3373 with docetaxel in patients with lung cancer. To date, we have seen notable tumor volume reductions and prolonged progression free survival in these patients. We look forward to sharing additional data from this trial later this year.”

Mr. Griffith concluded, “Lastly, we strengthened our balance sheet with a financing in May, extending our cash runway through key value-driving milestones. With multiple data readouts ahead, we are well-positioned to deliver on our mission of improving treatment outcomes for patients with cancer.”

2025 Anticipated Milestones

NUC-7738 Initiate an expansion of the Phase 1/2 study (NuTide:701) of NUC-7738 in combination with pembrolizumab in patients with PD-1 inhibitor-resistant melanoma;Announce data from the Phase 1/2 expansion study (NuTide:701) of NUC-7738 in combination with pembrolizumab; andObtain regulatory guidance from the U.S. Food and Drug Administration on pivotal study design for NUC-7738 in melanoma.
NUC-3373 Announce additional data from the Phase 1b/2 modular study (NuTide:303) of NUC-3373 in combination with pembrolizumab in patients with solid tumors.
First Quarter 2025 Financial Highlights and Cash Position

As of March 31, 2025, NuCana had cash and cash equivalents of £4.0 million compared to £6.7 million at December 31, 2024. Subsequent to March 31, 2025, NuCana

Is there news ? Active now

Looks nice here

https://www.gurufocus.com/news/2990186/nucana-ncna-finalizes-cancellation-of-series-a-warrants-ncna-stock-news

NCNA: effective August 8,2025 a one for 200 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

Good God! Don't go by bartchart.com 🤦‍♂️ imo it's crap!

when I……

….

use bar charts, its only to see what gapped down or up and some of the penny stock charts, i simply jot them down, study how they moved in the past, and decide if they are good to get at the time. but i would never go with their “advice”.

i use finviz the same way. i like to find the highest volume stocks and then go and see why it is and decide as it may be for a bad reason vs just good.

LOl, nice jab. No, trading mirrors what barchart lists. Keep up the good work

bar chart is your guide? wow.

Barchart says 100% sell so not really manipulation or panic. Just waiting for the chart to reset to get an entry

stocktwits is saying that it…..

…

is only on the offering shares. others are agreeing to that. all that is over my head but it caused panic selling. my hope is it goes back up next week, as it was just popping recently. its all manipulation on all of these, so we just ave to play the game. average down and wait for the next run.

So no R/S?

they just announced an…….

…

r/s but not for another month and someone posted this, over on stocktwits, so this is good news…

the split is for the ads offering shares which have already been rescinded. This does not pertain to retail and whoever can't produce those shares by August 11th is cooked!

grabbed some

NCNA: from the June 27th Prospectus: Ordinary shares to be outstanding immediately after this offering

34,540,891,147 ordinary shares (including those ordinary shares represented by ADSs), assuming no Series A ADS Purchase Warrants, or Series A Warrants, are exercised.

That's a lot o' shares!!!

https://www.sec.gov/edgar/search/#/ciks=0001709626&entityName=NuCana%2520plc%2520(NCNA)%2520(CIK%25200001709626)

$NCNA Merck could acquire them before cancer drug data:

https://www.reddit.com/r/NucanaPLC/comments/1lvknib/merck_just_bought_veronanext_up_nucana/

$NCNA 💹

Someone on here said Merck was going to present a deal in two weeks. Instead of calling bullshit, I did my research. Meanwhile, the FDA gives Merck “flagship approval” to use its top-selling drug Keytruda. So what, right? Well, let a monkey be my uncle—it just so happens Merck’s FDA approval to expand Keytruda’s use in resectable head and neck squamous cell carcinoma (PD-L1?≥1)—its first perioperative label in this cancer type—is a tailwind for NuCana’s Keytruda-based collaborations. Broader Keytruda use raises baseline demand. As oncologists adopt it in new settings, combo trials like NUC-3373 and NUC-7738 gain traction among prescribers and trial designers. Stronger biotech partnership perception. An expanding label reflects Merck’s confidence in Keytruda’s combinability—NuCana benefits by association, boosting investor and CRO interest. NuCana’s ProTide candidates are built to complement PD-1 blockade. More approved uses ease integration into regimens.

78 million series A warrants....356 million series B warrants....massive s-1 dilution in april and company has no cash...dilute then RS

150 million short yesterday and 539 million short tuesday says you have lost your mind...lol...u read too many story boards

Go. Ncna. Hope. Merck. Says something????

Go. Ncna. Tripled profit on this. !!!

Merck. Buyout. Would be awesome

NO YA DID NOT CLOWN...U BUY NOTHING...EVER....POPS IN ON HIS WORK BREAK AND PRETENDS

i hope that the merck buyout…..

….

for next week, rumor, is true. we need that type of news soon.

uh oh, its crashing a/h, maybe it bounces tomorrow.

merck that is, too late to edit my prior post.

others are posting about merc possibly buying ….

….

out ncna, and the info posted about them downsizing and filing for bk is to position themself for a buy out. thats all over my head but thats what it being said over on stocktwits.

no idea, but its going the wrong way.

How many shares OS? Over 2 billion just traded the other day

per google, AI Overview, there is a strong possibility that Merck may be interested in a partnership or acquisition of Nucana due to the promising results of their shared clinical trials.